Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration
- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceuti...
Maypharm's Hyalmass filler with Hybrid Technology obtained CE to hit Europe and America's market
SEOUL, South Korea and NEW YORK, April 18, 2023 /PRNewswire/ -- Being already popular onSouth Asia market, particularly in Vietnam, Philippines, Thailand, China, for Hybrid Technology and highly dense HA for long-lasting effect, Hyalmass filler obtains CE to properly enterEurope, America etc mark...
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries
* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil and Mexico in last February * Aiming to enter 50 countries by 2030 SEOUL, South Korea, March 22, 2023 /PRNewswire/ -- Daewoong Pharmaceutical began the advance into the global market in full swin...
Maypharm CO, LTD., launched a new CE filler: Multi-layered Phasic Hyaluronic Acid with lidocaine and CE approved MayFill Filler
SEOUL, South Korea and NEW YORK, Feb. 20, 2023 /PRNewswire/ -- Maypharm, a brand holder of such popular products as Metoo fill, Sedy fill, Metox, Mennus, Hairna, Eyebella, has been busy with developing new products in Aestheticians market. Metoo Fill is the first CE approved filler made by Maypha...
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted toColombia ,Vietnam, and Saudi Arabia * NDA submissions in 11 countries completed in the shortest time among K...
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030
* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40.4 billion * Fexuclue, a new drug released last July, shows steep growth in market share in Korea * Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastrit...
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030
* Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong), the South Korea -based global healthcare company, announced the phase III clinical tri...
CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA
* Embarking on a successful journey of exporting its home-grown product technology toNorth America, the largest market for bone substitutes * Enabling fast bone formation by applying bone morphogenetic protein (rhBMP-2) and next-generation synthetic carrier SEOUL, South Korea and LEWISVILLE, ...
Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever
- Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in operating revenue in the second quarter due to the growth of ethical drugs and Nabota. - A continuous increase in profitability is expected due to sales visualization of the new drug Fexuclue and Na...
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 * First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach$6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean p...
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
Daewoong Pharmaceutical announced first-quarter 2022 results
- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies * Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea ,April 12, 2022 /PRNewswire/ -- HanAll...
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, Marc...
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
